Ankylosing Spondylitis Market

1. Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast to 2030 The global Ankylosing Spondylitis Market size was valued at USD 5.8 billion in 2021 and is projected to reach around USD 10.6 billion in 2030 exhibiting a CAGR of 9.0% in the forecasted period. The development of new products, as well as the entrance of biosimilars are expected to upsurge the market growth. Moreover, the rising prevalence of the disease is also predicted to boost the market. As per the study published in Oxford University Press, the number of incidences in Europe was 1.30 to 1.56 million and 4.63 to 4.98 million in the Asia Pacific. However, high cost of ankylosing spondylitis treatment and severe effects of drugs used for cure of ankylosing spondylitis is hampering the growth of the market in the forecasted period. Request https://wemarketresearch.com/reports/request-free-sample-pdf/ankylosing-spondylitis- market/853 Free Sample Copy of this Report@ The marketing of new products and growing collaborations between corporations are projected to hasten market growth. For instance, in August 2019, Eli Lilly and Company got U.S. FDA approval for its product, Taltz injection 80 mg/mL, for the cure of active ankylosing spondylitis. Preceding to this approval, the product was accepted for active psoriatic arthritis and modest to severe plaque psoriasis in March 2016 and December 2017 respectively.

2. Additionally, in September 2018, Gilead Sciences, Inc. and Galapagos NV co-developed a product, Filgotinib, which has finished a phase 2 clinical trial for the sign of moderately to adversely active ankylosing spondylitis. The patent cliff has directed the entry of biosimilars into the market. These may expand patient access and fuel the market growth. In November 2019, the U.S. FDA permitted Humira’s biosimilar, Abrilada, for the management of certain indications including ankylosing spondylitis. Accessing medical services can be puzzling for people with ankylosing spondylitis throughout the COVID-19 pandemic. Though some drugs for ankylosing spondylitis can be self- administered, some are given via an IV in hospitals. Likewise, physical therapy needs a visit to the physical therapist, which has been problematic due to the COVID-19 pandemic. Biologics such as TNF (Tumor Necrosis factor) inhibitors, used in ankylosing spondylitis treatment, may upsurge the jeopardy of infections and worse the body's capacity to fight contaminations, including COVID-19, as these medications cause an overpowering effect on the immune system. Biologics containing IL-17 and IL-12/23 inhibitors are used for treating ankylosing spondylitis, but have the same immunosuppressive effect that may increase the risk of infections. Thus, the development of the global ankylosing spondylitis market is expected to be hindered. Secure https://wemarketresearch.com/purchase/ankylosing-spondylitis-market/853?license=single A Copy Of The Premium Research Report@ Competitive Analysis Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, Johnson & Johnson Services, Inc. About We Market Research: WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep-rooted market studies and insightful analysis of different markets. Contact Us: We Market Research Phone: +1(650)-666-4592 Email: sales@wemarketresearch.com Web: https://wemarketresearch.com/